AVENUE THERAPEUTICS, INC. Business Finance Contracts & Agreements
37 Contracts & Agreements
- Credit Agreements (1 contract)
- Facility Agreements (1)
- Guaranty Agreements (1)
- Note Agreements (1)
- Purchase Agreements (4)
- Registration Rights Agreements (4)
- Stock Agreements (2)
- Underwriting Agreements (6)
- Waiver Agreements (1)
- Warrant Agreements (16)
- Form of Securities Purchase Agreement, dated October 31, 2023, by and among Avenue Therapeutics, Inc. and the investors party thereto (Filed With SEC on November 2, 2023)
- Warrant Agent Agreement, dated October 31, 2023 by and between Avenue Therapeutics, Inc. and VStock Transfer, LLC (Filed With SEC on November 2, 2023)
- Form of Pre-funded Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Form of Series B Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Form of Series A Warrant (November 2023) (Filed With SEC on November 2, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on October 24, 2023)
- Form of Warrant Agent Agreement (Filed With SEC on October 24, 2023)
- Form of Warrant (Filed With SEC on October 24, 2023)
- Form of Warrant Agent Agreement (Filed With SEC on September 29, 2023)
- Form of Pre-funded Warrant (Filed With SEC on September 29, 2023)
- Registration Rights Letter Agreement, dated September 8, 2023, by and among the Company and the purchaser parties thereto (Filed With SEC on September 8, 2023)
- Form of Avenue Therapeutics, Inc. Stock Option Agreement (Filed With SEC on July 5, 2023)
- Registration Rights Agreement by and between the Company and AnnJi Pharmaceutical Co. Ltd., dated February 28, 2023 (Filed With SEC on May 12, 2023)
- Form of Registration Rights Agreement, dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Form of PIPE Warrant (PIPE) (Filed With SEC on February 1, 2023)
- Form of Pre-Funded Warrant (Registered Offering) (Filed With SEC on February 1, 2023)
- Form of Securities Purchase Agreement (PIPE), dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Form of Securities Purchase Agreement (Registered Offering), dated January 27, 2023, by and among the Company and the purchaser party thereto (Filed With SEC on February 1, 2023)
- Warrant Agent Agreement, dated October 6, 2022, by and between the Company and VStock Transfer, LLC (Filed With SEC on October 12, 2022)
- Form of Pre-funded Warrant (Filed With SEC on October 12, 2022)
- Form of Warrant (Filed With SEC on October 12, 2022)
- Underwriting Agreement, dated October 6, 2022, by and between the Company and Aegis Capital Corp (Filed With SEC on October 12, 2022)
- Form of Warrant Agent Agreement (Filed With SEC on October 5, 2022)
- Form of Pre-funded Warrant (Filed With SEC on October 5, 2022)
- Form of Warrant (Filed With SEC on October 5, 2022)
- Form of Underwriting Agreement (Filed With SEC on October 5, 2022)
- Stock Contribution Agreement between Avenue Therapeutics, Inc. and Fortress Biotech, Inc., dated May 11, 2022 (Filed With SEC on August 15, 2022)
- Underwriting Agreement, dated December 12, 2021, between Avenue Therapeutics, Inc. and Aegis Capital Corp., as representative of the several underwriters named therein (Filed With SEC on December 13, 2021)
- Underwriting Agreement, dated November 9, 2021, between Avenue Therapeutics, Inc. and AEGIS Capital Corp., as representative of the several underwriters named therein (Filed With SEC on November 10, 2021)
- Facility Agreement, dated June 12, 2020, by and between Avenue Therapeutics, Inc., InvaGen Pharmaceuticals Inc., and Fortress Biotech, Inc (Filed With SEC on August 14, 2020)
- Registration Rights Agreement, dated February 8, 2019, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on February 11, 2019)
- Waiver Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Guaranty, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Credit Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Amendment No. 1 to Promissory Note from Avenue Therapeutics, Inc. to Fortress Biotech, Inc. effective as of May 15, 2017 (Filed With SEC on March 1, 2018)
- [__________] Shares* Avenue Therapeutics, Inc. Common Stock FORM OF UNDERWRITING AGREEMENT (Filed With SEC on June 23, 2017)
- [__________] Shares* Avenue Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on May 22, 2017)
